Eleftherios P Mamounas Selected Research

Drug Therapy (Chemotherapy)

11/2023	Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.
1/2023	Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial.
1/2023	Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer.
9/2022	Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE.
6/2022	Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
10/2020	Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831.
11/2019	Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination.
1/2019	Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
1/2019	Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer.
1/2019	Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eleftherios P Mamounas Research Topics

Disease

113	Breast Neoplasms (Breast Cancer) 02/2024 - 08/2002
41	Neoplasms (Cancer) 02/2024 - 08/2002
9	Pathologic Complete Response 06/2023 - 11/2003
8	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2021 - 08/2007
5	Neutropenia 11/2023 - 01/2012
5	Amenorrhea 05/2021 - 01/2005
5	Neoplasm Metastasis (Metastasis) 12/2019 - 03/2008
5	Margins of Excision 12/2019 - 02/2008
4	Fatigue 01/2021 - 09/2015
3	Cardiotoxicity 01/2023 - 11/2005
3	Heart Failure 01/2023 - 10/2005
3	Hypertension (High Blood Pressure) 12/2017 - 01/2012
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2023 - 11/2012
2	Breast Diseases (Breast Disease) 01/2020 - 02/2017
2	Carcinoma (Carcinomatosis) 11/2019 - 01/2012
2	Residual Neoplasm 01/2019 - 03/2013
2	Left Ventricular Dysfunction 01/2019 - 01/2012
2	Hand-Foot Syndrome 09/2015 - 01/2012
2	Hypersensitivity (Allergy) 10/2010 - 10/2007
2	Febrile Neutropenia 02/2010 - 12/2002
2	Cicatrix (Scar) 11/2008 - 01/2006
1	Leukemia 02/2024
1	Overweight 11/2023
1	Nausea 01/2020
1	Vomiting 01/2020
1	Constipation 01/2020
1	Arthralgia (Joint Pain) 01/2019
1	Urinary Tract Infections (Urinary Tract Infection) 01/2019
1	Back Pain (Backache) 01/2019
1	Circulating Neoplastic Cells 01/2018
1	Hyperlipidemias (Hyperlipidemia) 12/2017
1	Heart Diseases (Heart Disease) 12/2017
1	Necrosis 03/2017
1	Embolism (Embolus) 02/2016
1	Thrombosis (Thrombus) 02/2016
1	Musculoskeletal Pain 02/2016
1	Sudden Death 09/2015
1	Endocarditis 09/2015
1	Triple Negative Breast Neoplasms 07/2014
1	Unilateral Breast Neoplasms 02/2014
1	Osteonecrosis (Kienbock's Disease) 07/2012

Drug/Important Bio-Agent (IBA)

30	Trastuzumab (Herceptin)FDA Link 06/2023 - 10/2003
26	Tamoxifen FDA LinkGeneric 11/2023 - 08/2002
23	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2017 - 12/2002
22	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2023 - 12/2002
21	Estrogen ReceptorsIBA 01/2021 - 10/2003
20	Hormones (Hormone)IBA 02/2024 - 08/2002
14	Paclitaxel (Taxol)FDA LinkGeneric 06/2023 - 06/2005
12	AnthracyclinesIBA 02/2024 - 11/2005
12	Docetaxel (Taxotere)FDA Link 08/2017 - 12/2002
11	B 31IBA 01/2023 - 10/2005
10	Aromatase InhibitorsIBA 02/2024 - 08/2002
7	human ERBB2 proteinIBA 01/2021 - 11/2005
6	Letrozole (Femara)FDA LinkGeneric 02/2024 - 05/2003
6	Progesterone Receptors (Progesterone Receptor)IBA 01/2021 - 06/2005
6	ErbB Receptors (EGF Receptor)IBA 01/2020 - 11/2005
6	desintegron BIBA 10/2016 - 10/2003
6	Anastrozole (Arimidex)FDA LinkGeneric 02/2016 - 08/2002
4	Lapatinib (GW572016)FDA Link 06/2023 - 11/2013
4	Biomarkers (Surrogate Marker)IBA 01/2023 - 04/2015
4	Ado-Trastuzumab EmtansineIBA 09/2022 - 01/2019
4	taxaneIBA 01/2020 - 09/2013
4	Bevacizumab (Avastin)FDA Link 07/2017 - 01/2012
4	Gemcitabine FDA Link 09/2015 - 01/2004
3	Capecitabine (Xeloda)FDA Link 01/2019 - 01/2012
3	Taxoids (Taxanes)IBA 01/2012 - 10/2003
3	exemestane (Aromasin)FDA Link 04/2008 - 05/2003
2	palbociclibIBA 11/2023 - 01/2021
2	B 43IBA 01/2021 - 11/2013
2	Clodronic Acid (Clodronate)IBA 01/2021 - 07/2012
2	Epirubicin (Ellence)FDA LinkGeneric 01/2017 - 02/2010
2	Diphosphonates (Bisphosphonates)IBA 07/2012 - 10/2003
2	Coloring Agents (Dyes)IBA 10/2010 - 10/2007
1	2- benzylidene- 3- (cyclohexylamino)- 2,3- dihydro- 1H- inden- 1- oneIBA 02/2024
1	Antineoplastic Agents (Antineoplastics)IBA 01/2023
1	N-acetyltalosaminuronic acid (NAT)IBA 01/2023
1	TRPC6 Cation ChannelIBA 01/2023
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 10/2022
1	Epidermal Growth Factor (EGF)IBA 09/2022
1	Zoledronic Acid (Zometa)FDA Link 01/2021
1	N- benzhydryl- 5- (2- (methylamino)propanamido)- 3- (3- methylbutanoyl)- 6- oxodecahydropyrrolo(1,2- a)(1,5)diazocine- 8- carboxamideIBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2020
1	Cytotoxins (Cytolysins)IBA 01/2019
1	Immunoconjugates (Immunoconjugate)IBA 01/2019
1	Maytansine (Maitansine)IBA 01/2019
1	130-nm albumin-bound paclitaxelIBA 04/2016
1	OF 743IBA 11/2012

Therapy/Procedure

57	Therapeutics 02/2024 - 08/2002
31	Drug Therapy (Chemotherapy) 11/2023 - 12/2002
29	Neoadjuvant Therapy 01/2023 - 04/2003
20	Adjuvant Chemotherapy 10/2020 - 12/2002
19	Segmental Mastectomy (Lumpectomy) 06/2022 - 10/2002
10	Radiotherapy 01/2022 - 10/2002
8	Mastectomy (Mammectomy) 12/2019 - 08/2006
4	Lymph Node Excision (Lymph Node Dissection) 05/2015 - 08/2007
2	Operative Surgical Procedures 01/2023 - 10/2003
2	Simple Mastectomy 06/2022 - 10/2008
2	Molecular Targeted Therapy 10/2005 - 10/2003
1	Combination Drug Therapy (Combination Chemotherapy) 09/2013
1	Adjuvant Radiotherapy 11/2012